Novartis stock pre-market at EUR 125.99: plus 0.27 percent
Published on 10/01/2026 at 08:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis stock was at EUR 125.99 pre-market at 8:31 a.m. CEST on October 1, 2026, according to Lang & Schwarz. That was an increase of 0.27 percent versus the Lang & Schwarz prior close of EUR 125.65 on September 30, 2026. The bid was EUR 125.76 and the ask was EUR 126.22. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Novartis stock.
Previous closing level
The prior closing level at Lang & Schwarz was EUR 125.65 on September 30, 2026. The current pre-market quote is stated separately from company developments.
Remibrutinib trial update
In a September 1, 2026 ad hoc announcement, Novartis said its Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing multiple sclerosis met their primary endpoint. The company said remibrutinib significantly reduced annualized relapse rates versus teriflunomide and showed superiority on key secondary endpoints, including MRI lesion reduction.
Novartis also reported a favorable safety profile in the trials, including no liver safety signal. The company said it planned to present late-breaking data at MSToronto2026 and intended to seek regulatory approval for remibrutinib in relapsing multiple sclerosis globally.
